Literature DB >> 20443640

Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.

Goutam Chowdhury1, Norie Murayama, Yusuke Okada, Yasuhiro Uno, Makiko Shimizu, Norio Shibata, F Peter Guengerich, Hiroshi Yamazaki.   

Abstract

(R)-Thalidomide was oxidized to 5-hydroxythalidomide and 5'-hydroxythalidomide by NADPH-fortified liver microsomes from humans and monkeys. (R)-Thalidomide was hydroxylated more efficiently than (S)-thalidomide. Recombinant human P450s 3A4, 3A5, and 3A7 and monkey P450s 3A8 and 3A5 (coexpressed with NADPH-P450 reductase in bacterial membranes) also catalyzed (R)-thalidomide 5-hydroxylation. Purified human P450s 2C19, 3A4, and 3A5 mediated (R)-thalidomide 5-hydroxylation at similar rates in reconstituted systems. P450 2C19 showed a rather nonsaturable substrate-velocity curve; however, P450s 3A4 and 3A5 showed sigmoidal curves. P450 also oxidized 5-hydroxythalidomide to an epoxide or dihydroxy compound. Liquid chromatography-mass spectrometry analysis revealed the formation of a glutathione conjugate from (R)- and (S)-5-hydroxythalidomide, catalyzed by liver microsomal P450s 3A4 and 3A5 in the presence of glutathione (assigned as a conjugate of 5-hydroxythalidomide formed on the phenyl ring). These results indicate that human P450s 3A4 and 3A5 mediate thalidomide 5-hydroxylation and further oxidation leading to a glutathione conjugate, which may be of relevance in the pharmacological and toxicological actions of thalidomide.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20443640      PMCID: PMC3843493          DOI: 10.1021/tx900367p

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  35 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations.

Authors:  H Yamazaki; A Okayama; N Imai; F P Guengerich; M Shimizu
Journal:  Xenobiotica       Date:  2006-12       Impact factor: 1.908

3.  Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro.

Authors:  J M Hansen; E W Carney; C Harris
Journal:  Reprod Toxicol       Date:  1999 Nov-Dec       Impact factor: 3.143

4.  The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species.

Authors:  H Schumacher; R L Smith; R T Williams
Journal:  Br J Pharmacol Chemother       Date:  1965-10

5.  Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients.

Authors:  S K Teo; P J Sabourin; K O'Brien; K A Kook; S D Thomas
Journal:  J Biochem Mol Toxicol       Date:  2000       Impact factor: 3.642

6.  Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.

Authors:  Norie Murayama; Naoko Imai; Takahisa Nakane; Makiko Shimizu; Hiroshi Yamazaki
Journal:  Biochem Pharmacol       Date:  2007-03-19       Impact factor: 5.858

7.  Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.

Authors:  C B Trapnell; S R Donahue; J M Collins; D A Flockhart; D Thacker; D R Abernethy
Journal:  Clin Pharmacol Ther       Date:  1998-12       Impact factor: 6.875

8.  Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism?

Authors:  Yasuhiro Uno; Shinya Hosaka; Kiyomi Matsuno; Chika Nakamura; Go Kito; Tetsuya Kamataki; Ryoichi Nagata
Journal:  Arch Biochem Biophys       Date:  2007-07-14       Impact factor: 4.013

9.  Thalidomide metabolism by the CYP2C subfamily.

Authors:  Yuichi Ando; Eiichi Fuse; William D Figg
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

Review 10.  Cytochrome p450 and chemical toxicology.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2007-12-06       Impact factor: 3.739

View more
  18 in total

1.  In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Makiko Shimizu; Sho Igaya; Norio Shibata; Masato Nakamura; Goutam Chowdhury; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-01-25       Impact factor: 3.739

2.  In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Norie Murayama; Masahiro Utoh; Norio Shibata; Masato Nakamura; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-03-01       Impact factor: 3.739

3.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

4.  Characterization of SfmD as a Heme peroxidase that catalyzes the regioselective hydroxylation of 3-methyltyrosine to 3-hydroxy-5-methyltyrosine in saframycin A biosynthesis.

Authors:  Man-Cheng Tang; Cheng-Yu Fu; Gong-Li Tang
Journal:  J Biol Chem       Date:  2011-12-20       Impact factor: 5.157

5.  In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Sho Igaya; Makiko Shimizu; Norio Shibata; Masato Nakamura; Goutam Chowdhury; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2011-02-07       Impact factor: 3.739

6.  The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage.

Authors:  Tasaduq H Wani; Anindita Chakrabarty; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich; Goutam Chowdhury
Journal:  Chem Res Toxicol       Date:  2017-08-02       Impact factor: 3.739

7.  Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor.

Authors:  Norie Murayama; Rinie van Beuningen; Hiroshi Suemizu; Christiane Guguen Guillouzo; Norio Shibata; Kanako Yajima; Masahiro Utoh; Makiko Shimizu; Christophe Chesné; Masato Nakamura; F Peter Guengerich; René Houtman; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2014-02-05       Impact factor: 3.739

8.  Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Yasuhiro Kazuki; Ken Oofusa; Shunji Kuribayashi; Makiko Shimizu; Shinichi Ninomiya; Toru Horie; Norio Shibata; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-07-29       Impact factor: 3.739

Review 9.  Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.

Authors:  Hiroshi Yamazaki; Hiroshi Suemizu; Marina Mitsui; Makiko Shimizu; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2016-07-05       Impact factor: 3.739

10.  Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice.

Authors:  Sayako Nishiyama; Hiroshi Suemizu; Norio Shibata; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Chem Res Toxicol       Date:  2015-10-26       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.